Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy
African Health Sciences · 2023
DOI: 10.4314/ahs.v23i2.14 ↗Kurz gefasst
Fachartikel in der Zeitschrift African Health Sciences, 2023. Verfasst von İpek Coşkunol und 4 weiteren Autor:innen. Beteiligte Einrichtung: Izmir Atatürk Research and Training Hospital, Chest Diseases Department, İzmir-Turkey. Hauptthemen laut MEDLINE: Latent Tuberculosis, Spondylitis, Ankylosing, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Setting-Objective: In this study, it was aimed to reveal the incidence of tuberculosis development in patients receiving tumor necrosis factor-alpha (TNF-α) blocker therapy, despite tuberculosis chemoprophylaxis.
Design
520 patients who were receiving anti TNF-α treatment in the last 3 years were evaluated retrospectively. Radiological imaging tuberculin skin test (TST), history of tuberculosis, BCG vaccine, chemoprophylaxis administration, used anti TNF-α drugs were recorded.
Results
There were 265(51.0%) of the patients with ankylosing spondylitis (AS), 175(33.7%) with rheumatoid arthritis, 35(6.7%) with Crohn's, 10(1.9%) with ulcerative colitis (UC), 21(4.0%) with psoriatic arthritis, 14(2.7%) with psoriasis vulgaris. In total, 455 (79.6%) patients were given INH prophylaxis. Active tuberculosis development was observed in five patients (4: pulmonary,1: extrapulmonary; 3: UC, 2:AS) who all received anti TNF-α treatment (0.96%), infliximab. Three patients had tuberculosis disease in the 6th month, and the other 2 patients in the 5th and 24th month of their anti TNF-α treatments, and two had 9-month, and 1 had 6-month chemoprophylaxis history.
Conclusion
The incidence of tuberculosis development in patients treated with anti TNF-α was found to be higher than the general population. In our country, where tuberculosis is still prevalent, patients receiving Anti TNF-α treatment (especially infliximab) should be carefully questioned and examined about tuberculosis. Keywords: Anti-TNF-alpha; tuberculosis; tuberculin skin test.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Izmir Atatürk Research and Training Hospital, Chest Diseases Department, İzmir-Turkey.
- Izmir Katip Celebi University, Chest Diseases Department, izmir-Turkey.
- Çamlica Medipol University Hospital, Chest Diseases Department, İstanbul -Turkey.
- Izmir Katip Celebi University, Rheumatology Department, İzmir -Turkey.
- Dokuz Eylül University, Rheumatology Department, İzmir-Turkey.
Zitieren
APA
Coşkunol, İ., Turan, O., Baysak, A., Solmaz, D., & Can, G. (2023). Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy. African Health Sciences. https://doi.org/10.4314/ahs.v23i2.14
Vancouver
Coşkunol İ, Turan O, Baysak A, Solmaz D, Can G. Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy. African Health Sciences. 2023. doi:10.4314/ahs.v23i2.14
BibTeX
@article{Cokunol2023,
author = {Coşkunol, İpek and Turan, Onur and Baysak, Aysegul and Solmaz, Dilek and Can, Gerçek},
title = {Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy},
journal = {African Health Sciences},
year = {2023},
doi = {10.4314/ahs.v23i2.14}
}
EUVIMED